Physician profile
Anthony Flaim
NPI 1497867311
$499.51
in general payments reported to CMS, 2019-2025
16 companies · $95.04 in 2025
The $95.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $55.50 · 2021: $77.47 · 2024: $110 · 2025: $95.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $97.93 | 2024-2025 | Arikayce |
| Novo Nordisk INC | $72.27 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $53.31 | 2019-2020 | |
| Genentech USA, INC. | $45.55 | 2019 | |
| Astellas Pharma US INC | $44.89 | 2020-2021 | |
| Amarin Pharma, INC. | $28.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2019 | |
| Merck Sharp & Dohme LLC | $18.38 | 2024 | Verquvo |
| Inogen, INC. | $16.60 | 2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $15.66 | 2019 | |
| Emd Serono, INC. | $15.26 | 2019 | |
| Pfizer INC. | $15.07 | 2021 | |
| Abbvie INC. | $14.31 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Lilly USA, LLC | $13.83 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Flaim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.